A response to a previously published article or letter can be submitted to the Online Correspondence section at http://www.anaesthesiacorrespondence.com. Please note that a selection of this correspondence will be reproduced (possibly in modified form) in the journal. All correspondence intended for publication in Anaesthesia should be addressed to Dr Steve Yentis, Editor-in-Chief, and submitted as an e-mail attachment to firstname.lastname@example.org. Copy should be prepared in the usual style of the Correspondence section. Authors must follow the advice about references and other matters contained in the Guidance for Authors at http://wileyonlinelibrary.com/journal/anae. Correspondence presented in any other style or format will be returned to the author for revision. All correspondence submissions should be accompanied by a completed Author Declaration Form which can be accessed via a link under ‘Covering letter’ in the Guidance for Authors (as above). The completed Author Declaration Form should be sent either by e-mail with the submission or by fax to (0)207 681 1008.
Aura-iTM laryngeal mask as a conduit for elective fibreoptic intubation
Article first published online: 12 OCT 2010
Anaesthesia © 2010 The Association of Anaesthetists of Great Britain and Ireland
Volume 65, Issue 11, page 1151, November 2010
How to Cite
McAleavey, F. and Michalek, P. (2010), Aura-iTM laryngeal mask as a conduit for elective fibreoptic intubation. Anaesthesia, 65: 1151. doi: 10.1111/j.1365-2044.2010.06528.x
- Issue published online: 12 OCT 2010
- Article first published online: 12 OCT 2010
The supraglottic airway’s usefulness as a dedicated airway has been the subject of considerable interest and is the subject of continuing development [1, 2]. Supraglottic airways have been used to facilitate tracheal intubation in situations where difficulty with conventional laryngoscopy has been predicted [3, 4].
We wish to report the use of a new disposable supraglottic airway, the Ambu Aura-iTM disposable intubating laryngeal mask (Ambu A/S, Ballerup, Denmark), as a conduit for fibreoptic tracheal intubation in a patient with predicted difficulty in airway management. We could find no similar reports in the English language.
The patient was a 42-year-old, 65-kg woman, ASA 1, scheduled to undergo elective breast surgery. She gave a history of trauma to her neck and jaw some years previously. On examination, we found her airway to be a Mallampati class 2, with mouth opening of approximately 3.5 cm and grade B jaw protrusion. She exhibited restricted craniocervical extension. Because of her slim build, we did not anticipate difficulty with mask ventilation. She was extremely anxious, and following discussion, we decided to proceed with fibreoptic intubation following induction of general anaesthesia.
The patient was premedicated with 10 mg temazepam. Anaesthesia was induced with 75 μg fentanyl and 150 mg propofol. Following confirmation of the ability to ventilate the patient’s lungs using a bag and facemask, we administered 40 mg atracurium. We subsequently confirmed loss of train-of-four response with a peripheral nerve stimulator. We then inserted a size-4 Ambu Aura-i without difficulty and inflated the cuff with 10 ml air. We achieved satisfactory ventilation after 12 s. We then used the Ambu Aura-i as a conduit to pass a size 7.5-mm tracheal tube (Teleflex Medical Ltd, High Wycombe, UK) into the trachea with the aid of an intubating bronchoscope. We gained a full view of the glottic opening from the end of the device. Satisfactory ventilation was confirmed in 27 s. Anaesthesia and emergence proceeded uneventfully.
The Ambu Aura-i is a newly available disposable supraglottic airway device that may prove useful in the management of the difficult airway. When compared with the commonly used LMA FastrachTM (Intavent Orthofix Ltd., Maidenhead, UK), the Aura-i readily accepts a standard tracheal tube (Fig. 3), but lacks an epiglottic elevating bar, which may be a disadvantage if intubation is attempted blindly, but could improve the camera view from the end of the device. Its disposable nature gives an improved infection control profile and it is significantly cheaper than the reusable device.
No external funding and no competing interests declared. Published with the patient’s written consent.